The Japanese Ministry of Health, Labor, and Welfare has approved Darzalex (daratumumab) in combination with either Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib)…
Adding Darzalex (daratumumab) to standard care therapies continues to show improved effectiveness in treating relapsed or refractory multiple myeloma, with no related toxicity, according to updated…
A three-drug therapy combination consisting of Darzalex (daratumumab) with Revlimid (lenalidomide) and Decadron (dexamethasone) shows real potential in increasing survival in patients with…
Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand Darzalex (daratumumab) to include…
